BioCentury | Sep 30, 2020
Distillery Therapeutics

Endogenous bile acid identified for obesity and diabetes

DISEASE CATEGORY: Endocrine/metabolic INDICATION: Obesity; diabetes GPBAR1 agonism via cholic acid-7-sulfate, a gut-restricted endogenous bile acid, could treat obesity and Type II diabetes. In people who had undergone sleeve gastronomy, post-surgery fecal samples had higher levels...
BioCentury | Aug 15, 2020
Product Development

Aug. 14 Quick Takes: Challenge data for CanSino COVID-19 vaccine; plus Warp Speed-McKesson, BioMarin, TG, Solasia-Isofol

CanSino vaccine stops COVID-19 in mice, ferretsMice given a single intranasal immunization with Ad5-nCoV from CanSino Biologics Inc. (HKEX:6185; Shanghai:688185) and then challenged with mouse-adapted SARS-CoV-2 had no detectable virus in the lungs and nose...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Oct 28, 2019
Clinical News

TG makes case for umbralisib as safer lymphoma option

Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial. TG Therapeutics...
BioCentury | Apr 5, 2019
Clinical News

TG reports response rate of 52% for lymphoma candidate

TG has reported detailed interim data from the pivotal Phase IIb UNITY-NHL trial supporting the company's decision to seek accelerated approval from FDA by year end for umbralisib (TGR-1202) to treat marginal zone lymphoma. At...
BioCentury | Mar 1, 2019
Clinical News

TG aims for accelerated approval of lymphoma candidate

TG Therapeutics Inc. (NASDAQ:TGTX) said umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal zone lymphoma patients in a pivotal Phase IIb trial. The biotech now plans to seek accelerated approval of the...
BioCentury | Feb 28, 2019
Clinical News

TG aims for accelerated approval of lymphoma candidate

TG Therapeutics Inc. (NASDAQ:TGTX) added $1.61 (31%) to $6.80 on Thursday after reporting that umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal zone lymphoma patients in a pivotal Phase IIb trial. The...
BioCentury | Jan 8, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated phosphorylation of PLC1, which...
BioCentury | Sep 28, 2018
Clinical News

TG won't seek accelerated approval of CLL combo

TG Therapeutics Inc. (NASDAQ:TGTX) shed $4.10 (44%) to $5.15 on Sept. 25 after the company said it will not seek accelerated approval of ublituximab (TG-1101) plus umbralisib (TGR-1202) to treat chronic lymphocytic leukemia. The company...
BioCentury | Sep 25, 2018
Clinical News

TG won't seek accelerated approval of CLL combo; shares sink

TG Therapeutics Inc. (NASDAQ:TGTX) shed $4.10 (44%) to $5.15 on Tuesday after the company said it will not seek accelerated approval of ublituximab (TG-1101) plus umbralisib (TGR-1202) to treat chronic lymphocytic leukemia. The company said...
Items per page:
1 - 10 of 88